#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	17330	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2154	799.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1440	1440	C	1019	C,T	947,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31716	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3534	893.9	0	.	n	.	0	T695C	SNP	695	695	T	946	946	C	959	C	903	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31716	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3534	893.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1588	1588	A	1026	A	958	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31716	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3534	893.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2222	2222	C	1095	C	997	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31716	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3534	893.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2296	2296	A	965	A	895	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31716	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3534	893.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	2848	2848	C	1023	C	949	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	27	2302	folP	855	855	100.0	folP.l15.c30.ctg.1	1610	141.8	1	SNP	p	R229S	0	.	.	685	687	CGC	967	969	CGC	231;228;229	C,A;G;C	212,1;213;210	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6136	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3383	180.7	1	SNP	p	S91F	0	.	.	271	273	TCC	607	609	TCC	201;201;203	T;C;C,T	189;191;190,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6136	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3383	180.7	1	SNP	p	D95G	0	.	.	283	285	GAC	619	621	GAC	201;200;200	G;A;C	189;189;189	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6136	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3383	180.7	1	SNP	p	D95N	0	.	.	283	285	GAC	619	621	GAC	201;200;200	G;A;C	189;189;189	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	1972	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1225	159.0	1	SNP	p	G45D	1	.	.	133	135	GAC	440	442	GAC	265;264;261	G;A,G;C	244;242,1;241	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1076	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1003	106.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	6316	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3013	209.1	1	SNP	p	D86N	0	.	.	256	258	GAC	565	567	GAC	252;252;253	G;A;C	234;232;236	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	6316	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3013	209.1	1	SNP	p	S88P	0	.	.	262	264	TCC	571	573	TCC	247;248;249	T;C;C	227;228;230	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4956	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2705	182.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1652	1654	GGC	266;266;267	G;G;C	250;247;243	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4680	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2430	191.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1285	1287	GCA	263;264;263	G;C;A	247;246;243	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4680	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2430	191.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1288	1290	ATC	265;267;266	A;T;C	245;248;245	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4680	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2430	191.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1300	1302	GTG	277;276;274	G;T;G	256;255;255	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4680	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2430	191.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1300	1302	GTG	277;276;274	G;T;G	256;255;255	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4680	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2430	191.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1804	1806	ACC	239;235;236	A;C;C	214;217;222	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4680	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2430	191.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1858	1860	GCG	240;242;245	G;C,G;G	209;198,1;210	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4680	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2430	191.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1858	1860	GCG	240;242;245	G;C,G;G	209;198,1;210	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4680	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2430	191.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1981	1983	GGC	200;200;200	G;G;C	188;189;187	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4680	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2430	191.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1990	1992	GGC	208;208;209	G,A;G;C	191,1;188;192	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4680	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2430	191.7	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2008	2010	CTG	202;201;201	C,G;T;G	159,4;146;161	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	6700	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3138	213.0	1	SNP	p	L421P	1	L421P	NONSYN	1261	1263	CTG	1686	1688	CCG	241;243;243	C;C;G,A	218;227;222,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2564	porA	1146	1146	99.83	porA.l15.c30.ctg.1	1727	147.4	0	.	p	.	0	S22G	NONSYN	64	66	AGC	384	386	GGC	165;168;167	G;G;C	150;152;149	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2564	porA	1146	1146	99.83	porA.l15.c30.ctg.1	1727	147.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	566	566	C	182	C	164	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3312	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1688	195.3	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	736	738	AAG	265;266;260	A;A;G	248;249;243	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3312	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1688	195.3	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	805	807	CAA	275;273;271	C;A;A	254;254;253	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3312	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1688	195.3	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1012	1014	GAT	281;278;278	G;A;T	269;267;264	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3312	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1688	195.3	0	.	p	.	0	H213G	NONSYN	637	639	CAT	1015	1017	GGT	275;280;277	G;G;T	262;268;258	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3312	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1688	195.3	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1030	1032	ATG	274;273;270	A;T;G	263;263;256	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3312	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1688	195.3	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1147	1149	ACG	241;240;239	A;C;G	227;227;227	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3312	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1688	195.3	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1153	1155	GTT	244;244;248	G;T;T	233;231;236	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3312	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1688	195.3	0	.	p	.	0	D294N	NONSYN	880	882	GAT	1258	1260	AAT	275;272;273	A;A;T	252;253;254	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3312	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1688	195.3	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1267	1269	AAC	268;264;264	A;A;C	248;246;247	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3312	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1688	195.3	1	SNP	p	D121N	0	.	.	361	363	GAC	739	741	GAC	264;260;260	G;A;C	247;243;243	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3312	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	1688	195.3	1	SNP	p	A121D	1	.	.	361	363	GAC	739	741	GAC	264;260;260	G;A;C	247;243;243	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12050	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	4858	247.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1274	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	969	129.3	1	SNP	p	V57M	1	.	.	169	171	ATG	433	435	ATG	244;247;246	A;T;G	226;229;227	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
